Vanda Pharmaceuticals (VNDA) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- Wall Street set for weekly gains with earnings, inflation data on tap
- Oil falls as Trump comments on Iran talks ease supply fears
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts VNDA Hot Sheet
Price: $4.56 +0.66%
EPS Growth %: -78.9%
Financial Fact:
Intangible asset amortization: 2.94M
Today's EPS Names:
HOVR, VFS, PGR, More
EPS Growth %: -78.9%
Financial Fact:
Intangible asset amortization: 2.94M
Today's EPS Names:
HOVR, VFS, PGR, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of ($0.05), in-line with the analyst estimate of ($0.05). Revenue for the quarter came in at $7.4 million versus the consensus estimate of $8.07 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Delta Air Lines (DAL) Misses Q3 EPS by 20c, Beats on Revenue; Cuts FY EPS Guidance
- Levi (LEVI) Tops Q3 EPS by 12c; raises guidance
- Apogee Enterprises (APOG) Tops Q2 EPS by 54c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
